Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised Phase II/III Study of Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia

NCT04061512 is registered in ClinicalTrials.gov with University College, London as lead sponsor.

NCT NCT04061512
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04061512 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised Phase II/III Study of Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia
Lead sponsor
University College, London
Phase
Phase 2/3
Overall status
Recruiting
Start date
February 3, 2020
Completion date
March 31, 2030
Enrollment
148 (estimated)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

waldenstrom macroglobulinemia